The hunt for a groundbreaking biomarker test for Parkinson’s disease continues with additional support from the world-renowned Michael J. Fox Foundation

Lundbeck is combining its biomarker discoveries with leading microfluidic experts at the Danish Technical University (DTU). This is to develop a state-of-the-art biomarker assay. The project aims to not only facilitate early diagnosis of neurodegenerative diseases. This is such as Parkinson’s disease and Multiple System Atrophy (MSA). But it also enable improved monitoring of disease progression and effects of disease-modifying therapies.

Three years ago, Lundbeck embarked on a journey to develop a validated biomarker test for Parkinson’s disease. It focused on the detection of minute amounts of pathological aggregates formed by the protein alpha-synuclein.